PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study finds key to calling back-up help when tumor-fighter p53 goes down

Genes p63, p73 can fill in to identify, destroy bad cells if they can be protected from themselves

2013-04-09
(Press-News.org) WASHINGTON, D.C. – Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

In a presentation at the AACR Annual Meeting 2013, scientists from The University of Texas MD Anderson Cancer Center demonstrate that tumor suppression can be restored in mice that lack p53 by knocking out the ∆N isoforms of p63 and p73 that interfere with tumor suppression. Isoforms are proteins made from the same gene that are often produced by alternative gene promoter usage or splicing.

"In many cancers, the tumor-suppressor p53 is inactivated by genetic mutations or is deleted outright, damage that is exploited by cancer to develop and grow," said study senior author Elsa Flores, Ph.D., associate professor in MD Anderson's Department of Biochemistry and Molecular Biology.

"We can use the other family members to compensate for the loss of p53 as we learn more about them and how they function," Flores said. Attempting to restore p53 expression in tumors has so far been largely ineffective in cancer treatment.

The youngest of the three genes, p53, was the first discovered in 1979. It controls the activity of dozens of other genes that detect abnormal cells during cell division, attempt to repair the damage and order the defective cell to kill itself if it can't be fixed.

Two protein forms: TA version inhibits cancer, ΔN version thwarts TA

The Human Genome Project identified p63 and p73 in 1997, Flores said. Both genes have a longer evolutionary history than p53 and can perform the same cancer-blocking function. Or rather, one isoform of each gene can do the job.

Research by Flores and others has shown that p63 and p73 come in two major isoforms: the transactivation versions (TAp63 and TAp73) that act like p53, and the Delta-N versions (ΔNp63 and ΔNp73), which appear to act as oncogenes, helping tumors form and grow by blocking suppressors.

Flores, study first author and presenter Avinashnarayan Venkatanarayan and colleagues knocked down ΔNp63 and ΔNp73 in a thymic lymphoma mouse model that lacked p53. Mice with ΔNp63 and ΔNp73 blocked had a lower incidence of lymphoma, and greater expression of genes usually targeted by p53 that regulate the cell cycle and promote death of abnormal cells.

"This suggests that ablating the ΔN isoforms facilitated increased activity by genes that induce cell cycle arrest and apoptosis that are downstream targets of p53," Venkatanarayan said.

Knocking out ∆Np63 and ∆Np73 shrinks tumors in mice that lack p53

To further demonstrate the effect, the researchers then deleted ΔNp63 and ΔNp73 by injecting adenoviral-CRE in the thymus of ∆Np63 and ∆Np73 conditional knockout mice with p53 knocked out. With the two inhibiting isoforms blocked, treated mice had significant tumor shrinkage within three weeks.

The team also found that ΔNp63 and ΔNp73 hinder tumor suppression by binding to the promoter sites of TAp63 and TAp73; further supporting the thesis that blocking the ΔN isoforms frees the TA versions to repress tumors.

A test in human cancer cell lines showed that knocking down ΔNp63 and ΔNp73 led to cell cycle arrest and apoptosis when p53 was completely deleted. In cell lines with mutated p53, TAp63 and TAp73 were prevented from activating tumor-killing genes by the mutated p53.

"Mutant p53 actually hinders its family members from taking up the tumor-suppressing cause when p53 is dysfunctional," Flores said. "Our research now focuses on overcoming the mutant p53 effect in these cancer cell lines.

### This research was funded by grants from the National Cancer Institute of the National Institutes of Health (R01CA134796), the Leukemia and Lymphoma Society of America, the Cancer Prevention and Research Institute of Texas, and a development award from MD Anderson's Lymphoma Specialized Program of Research Excellence, funded by a grant from NCI (5P50CA136411-03).

Co-authors with Flores and Venkatanarayan are Deepavali Chakravarti, Xiaohua Su, Ph.D., Santosh Sandur, Ph.D., Lingzhi Liu, Eliot Fletcher Sananikone, and Payal Raulji all of MD Anderson's Department of Biochemistry and Molecular Biology; William Norton, D.V.M. of MD Anderson's Department of Veterinary Medicine and Surgery; and Cristian Coarfa, Ph.D., and Preethi Gunaratne, Ph.D., the University of Houston Biology and Biochemistry Department.

Venkatanarayan and Chakravarti are both graduate students in The University of Texas Graduate School of Biomedical Sciences at Houston, a joint operation of MD Anderson and The University of Texas Health Science Center at Houston.


ELSE PRESS RELEASES FROM THIS DATE:

AACR news: XL-184 (Cabozantinib) goes 12-for-12 in colorectal cancer explants

2013-04-09
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013. "With molecularly targeted agents, we typically see 3 or 4 CRC explant models with a significant decrease in tumor growth. Here we have a drug that was active in every explant we tested. It's really exciting," says John Arcaroli, PhD, investigator at the University ...

AACR news: Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine

2013-04-09
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and so more susceptible to the drugs. That's what the traditional anti-malaria drug, chloroquine, does – it inhibits autophagy. Existing clinical trials are testing chloroquine/chemotherapy combinations against breast cancer. Research presented at the AACR Annual Meeting 2013 shows that some breast cancer subtypes depend on autophagy more than others – and ...

Possible predictive biomarker for patients who may respond to autophagy inhibitors

2013-04-09
WASHINGTON, DC – Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy. A team led by researchers from the ...

Surface diffusion plays a key role in defining the shapes of catalytic nanoparticles

2013-04-09
Controlling the shapes of nanometer-sized catalytic and electrocatalytic particles made from noble metals such as platinum and palladium may be more complicated than previously thought. Using systematic experiments, researchers have investigated how surface diffusion – a process in which atoms move from one site to another on nanoscale surfaces – affects the final shape of the particles. The issue is important for a wide range of applications that use specific shapes to optimize the activity and selectivity of nanoparticles, including catalytic converters, fuel cell ...

Thinking you're old and frail

2013-04-09
Older adults who categorise themselves as old and frail encourage attitudinal and behavioural confirmation of that identity. This is the conclusion of a study conducted by Krystal Warmoth and colleagues at University of Exeter Medical School, which is being presented today, 9th April 2013, at the British Psychological Society Annual Conference in Harrogate, UK. Krystal Warmoth interviewed 29 older adults in the South West of England face-to-face. Interviews conducted asked about their experiences of ageing and frailty. Self-perception and identification related to ...

Particles changing angle: Unexpected orientation in capillaries

2013-04-09
When small particles flow through thin capillaries, they display an unusual orientation behaviour. This has recently been discovered by a research team led by Prof. Stephan Förster and Prof. Walter Zimmermann (University of Bayreuth, Germany) at the X-ray sources DORIS III and PETRA III of the research centre DESY in Hamburg, Germany. The discovery is of major importance for spinning processes designed for the production of synthetic fibres, and for the understanding of vascular stenosis. The scientists of Bayreuth University, the Radboud University Nijmegen (Netherlands), ...

Moving cells with light holds medical promise

2013-04-09
Scientists at Washington University School of Medicine in St. Louis have shown they can coax cells to move toward a beam of light. The feat is a first step toward manipulating cells to control insulin secretion or heart rate using light. Their research is published April 8 in the Proceedings of the National Academy of Sciences Online Early Edition. "We have succeeded in using light as a kind of on-off switch to control cells' behavior," says principal investigator N. Gautam, PhD, a professor of anesthesiology. "Much of the way cells behave is due to their ability to ...

University of Tennessee professor's research shows Gulf of Mexico resilient after spill

2013-04-09
The Gulf of Mexico may have a much greater natural ability to self-clean oil spills than previously believed, according to Terry Hazen, University of Tennessee-Oak Ridge National Laboratory Governor's Chair for Environmental Biotechnology. The bioremediation expert presented his Deepwater Horizon disaster research findings at the 245th National Meeting and Exposition of the American Chemical Society (ACS), the world's largest scientific society. Hazen conducted research following the 2010 Deepwater Horizon disaster, which is estimated to have spilled 210 million gallons ...

A hijacking of healthy cellular circuits

2013-04-09
April 8, 2013, New York, NY and San Diego Calif. – Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor (EGFR), fuels a wide variety of cancers—including a highly malignant brain cancer known as glioblastoma. Yet drugs devised to block its signaling tend to work only for a short while, until the cancer cells adapt to evade the therapy. So far, much of the research examining such drug resistance has focused on how ...

A fly mutation suggests a new route for tackling ALS

2013-04-09
WASHINGTON, D.C. – April 8, 2013— A team of researchers, led by Marc Freeman, PhD, an early career scientist with the Howard Hughes Medical Institute and associate professor of neurobiology at the University of Massachusetts Medical School have discovered a gene in the fruit fly Drosophila melanogaster that, when mutant, blocks the self-destruction of damaged axons, which could hold clues to treating motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). A neuron has a very distinctive form – a bush of dendrites that receive signals, an incredibly long axon, ...

LAST 30 PRESS RELEASES:

Scientists reverse Alzheimer’s in mice using nanoparticles

‘Good’ gut bacteria boosts placenta for healthier pregnancy

USC team demonstrates first optical device based on “optical thermodynamics”

Microplastics found to change gut microbiome in first human-sample study

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

Yeast proteins reveal the secrets of drought resistance

Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition

New Canadian study reveals where HIV hides in different parts of the body

Lidocaine poisonings rise despite overall drop in local anesthetic toxicity

Politics follow you on the road

Scientists blaze new path to fighting viral diseases

The mouse eye as a window to spotting systemic disease

AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs

FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials

Exploring the therapeutic potential of cannabidiol for Alzheimer's

We need a solar sail probe to detect space tornadoes earlier, more accurately, U-M researchers say

Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results

Sperm microRNAs: Key regulators of the paternal transmission of exercise capacity

Seeing double: Clever images open doors for brain research

Inhaler-related greenhouse gas emissions in the US

UCLA Health study finds inhalers for asthma and COPD drive significant greenhouse gas emissions

A surgical handover system for patient physiology and safety

Cardiovascular health changes in young adults and risk of later-life cardiovascular disease

Nurse workload and missed nursing care in neonatal intensive care units

How to solve the remote work stalemate – dissertation offers tools for successful hybrid work

Chip-based phonon splitter brings hybrid quantum networks closer to reality

Texas Children’s researchers create groundbreaking tool to improve accuracy of genetic testing

Milken Institute, Ann Theodore Foundation announce more than $2.5 million in new funding for sarcoidosis research and launch new call for proposals

Boston University professor to receive 2025 Eugene Braunwald Academic Mentorship Award

[Press-News.org] Study finds key to calling back-up help when tumor-fighter p53 goes down
Genes p63, p73 can fill in to identify, destroy bad cells if they can be protected from themselves